# A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Source: https://onco.cc/trials/nct06456463/  
OnCo record `nct06456463` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tagraxofusp, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Stemline Therapeutics, Inc., active and no longer recruiting.

## Summary

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy is a phase 2 interventional study registered as NCT06456463 by Stemline Therapeutics, Inc., with 85 participants enrolled, started 2025-01-14 and due to reach its primary completion in 2028-02-09. Interventions recorded: Tagraxofusp, Venetoclax and Azacitidine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06456463
- Phase: 2
- Setting: A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy
- Sponsor: Stemline Therapeutics, Inc.
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06456463: https://clinicaltrials.gov/study/NCT06456463

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Tagraxofusp](https://onco.cc/drugs/tagraxofusp/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Menarini / Stemline](https://onco.cc/companies/menarini/)

---
JSON: https://onco.cc/api/v1/entities/nct06456463.json